These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 8822534)

  • 1. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
    Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
    Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
    Crawford AM; Beasley CM; Tollefson GD
    Schizophr Res; 1997 Jul; 26(1):41-54. PubMed ID: 9376336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
    Tollefson GD; Sanger TM; Beasley CM; Tran PV
    Biol Psychiatry; 1998 Jun; 43(11):803-10. PubMed ID: 9611669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing the antipsychotic medication olanzapine.
    Nemeroff CB
    J Clin Psychiatry; 1997; 58 Suppl 10():45-9. PubMed ID: 9265916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.
    Breier A; Meehan K; Birkett M; David S; Ferchland I; Sutton V; Taylor CC; Palmer R; Dossenbach M; Kiesler G; Brook S; Wright P
    Arch Gen Psychiatry; 2002 May; 59(5):441-8. PubMed ID: 11982448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
    Hamilton SH; Revicki DA; Genduso LA; Beasley CM
    Neuropsychopharmacology; 1998 Jan; 18(1):41-9. PubMed ID: 9408917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.
    Wright P; Meehan K; Birkett M; Lindborg SR; Taylor CC; Morris P; Breier A
    Clin Ther; 2003 May; 25(5):1420-8. PubMed ID: 12867218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.
    Lieberman JA; Tollefson G; Tohen M; Green AI; Gur RE; Kahn R; McEvoy J; Perkins D; Sharma T; Zipursky R; Wei H; Hamer RM;
    Am J Psychiatry; 2003 Aug; 160(8):1396-404. PubMed ID: 12900300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.
    Beasley CM; Sanger T; Satterlee W; Tollefson G; Tran P; Hamilton S
    Psychopharmacology (Berl); 1996 Mar; 124(1-2):159-67. PubMed ID: 8935812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia.
    Wright P; Birkett M; David SR; Meehan K; Ferchland I; Alaka KJ; Saunders JC; Krueger J; Bradley P; San L; Bernardo M; Reinstein M; Breier A
    Am J Psychiatry; 2001 Jul; 158(7):1149-51. PubMed ID: 11431240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
    Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
    J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina.
    Sacristán JA; Gómez JC; Montejo AL; Vieta E; Gregor KJ
    Clin Ther; 2000 May; 22(5):583-99. PubMed ID: 10868556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
    Ishigooka J; Inada T; Miura S
    Psychiatry Clin Neurosci; 2001 Aug; 55(4):403-14. PubMed ID: 11442893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America.
    Costa e Silva JA; Alvarez N; Mazzotti G; Gattaz WF; Ospina J; Larach V; Starkstein S; Oliva D; Cousins L; Tohen M; Taylor CC; Wang J; Tran PV
    J Clin Psychopharmacol; 2001 Aug; 21(4):375-81. PubMed ID: 11476121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment.
    Wright P; Lindborg SR; Birkett M; Meehan K; Jones B; Alaka K; Ferchland-Howe I; Pickard A; Taylor CC; Roth J; Battaglia J; Bitter I; Chouinard G; Morris PL; Breier A
    Can J Psychiatry; 2003 Dec; 48(11):716-21. PubMed ID: 14733451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.